Acute Kidney Injury (AKI), also known as acute renal failure (ARF), is a condition characterized by azotemia that progresses over several hours or days, with or without oliguria. AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to an abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.

Curious about the numbers? Dive into the data with our infographic: Click Here

Acute Kidney Injury Epidemiology Segmentation in the 7MM

• Total Incident Population of AKI in Hospitalized Patients
• Mortality-Adjusted Incident Population of AKI in Hospitalized Patients
• Stage-specific Incident Population of AKI
• Age-Specific Incident Population of AKI

Acute Kidney Injury Epidemiological Insights Observed in the 7MM

The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the 7MM comprised 14.6 million cases in 2022.

Acute Kidney Injury Market Insight

The total market size of Acute Kidney Injury in the 7MM was ~USD 6.2 billion in 2022 and is projected to grow during the forecast period (2024-2034).

Acute Kidney Injury Market Strengths

The pipeline of AKI is quite robust, with diverse products strengthening the upcoming market.

Acute Kidney Injury Market Opportunities

History and physical exams help identify causes of Acute Kidney Injury, such as nephrotoxic drugs or systemic illnesses. AKI diagnosis relies on serum creatinine increase or reduced urine output, with lab tests like creatinine, urinalysis, and renal biopsy providing further insights.

Acute Kidney Injury Emerging Drugs and Key Companies

• RBT-1 (Renibus Therapeutics)
• OCE-205 (Ocelot Bio)
• APX-115 (AptaBio Therapeutics) 
• Ilofotase alfa (AM-Pharma)
• bRESCAP (Alloksys Life Sciences)

Download the full infographic to uncover detailed insights: Click Here